Publications by authors named "Martin Hendrix"

Claim this Profile
P
Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
Frank G Boess, Jean de Vry, Christina Erb, Timo Flessner, Martin Hendrix

Psychopharmacology (Berl)· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.
F Josef van der Staay, Kris Rutten, Lars Bärfacker, Jean Devry, Christina Erb, Martin Hendrix

Neuropharmacology· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Frank G Boess, Jean De Vry, Christina Erb, Timo Flessner, Martin Hendrix

J Pharmacol Exp Ther· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Kris Rutten, Jos Prickaerts, Martin Hendrix, F Josef van der Staay, Ayhan Sik

Eur J Pharmacol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico ADMET traffic lights as a tool for the prioritization of HTS hits.
Mario Lobell, Martin Hendrix, Berthold Hinzen, Jörg Keldenich, Heinrich Meier

ChemMedChem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.
Tobias Wunberg, Martin Hendrix, Alexander Hillisch, Mario Lobell, Heinrich Meier

Drug Discov Today· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Frank Wunder, Adrian Tersteegen, Annegret Rebmann, Christina Erb, Thomas Fahrig, Martin Hendrix

Mol Pharmacol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
Frank G Boess, Martin Hendrix, Franz-Josef van der Staay, Christina Erb, Rudy Schreiber

Neuropharmacology· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
Ulrich A K Betz, Rüdiger Fischer, Gerald Kleymann, Martin Hendrix, Helga Rübsamen-Waigmann

Antimicrob Agents Chemother· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Gerald Kleymann, Rüdiger Fischer, Ulrich A K Betz, Martin Hendrix, Wolfgang Bender

Nat Med· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis